Literature DB >> 17115285

Expression of VEGFR3 in glioma endothelium correlates with tumor grade.

S J Grau1, F Trillsch, J Herms, N Thon, P J Nelson, J-C Tonn, R Goldbrunner.   

Abstract

Angiogenic processes are regulated by vascular endothelial growth factors (VEGFs) and their receptors VEGFR1 (Flt-1), 2 (Flk-1) and 3 (Flt-4). While VEGFR2 is thought to play a central role in tumor angiogenesis, anti-angiogenic therapies targeting VEGFR2 in glioma models can show escape phenomena with secondary onset of angiogenesis. The purpose of this study was to find explanations for these processes by searching for alternative pathways regulating glioma angiogenesis and reveal a correlation with tumor grade. Thus, VEGFR3, which is not expressed in normal brain, and its ligands VEGF-C and -D, were assessed in high grade (WHO degrees IV, glioblastomas, GBM) and low grade gliomas [WHO degrees II astrocytomas (AII)]. In all GBM, a strong protein expression of VEGFR3 was found on tumor endothelium, VEGF-C and -D expression was found on numerous cells in areas of high vascularization. On RNA level, a significant up-regulation of VEGFR3 was detected in GBM compared to AII and non-neoplastic brain. In AII, only very moderate VEGFR3, VEGF-C and -D expression was found on protein and RNA level indicating a correlation of VEGFR3 expression with tumor grade. VEGFR3 signal in both grades was found predominantly on endothelial cells, confirmed by VEGFR3 expression on isolated CD31 positive cells and the expression of various endothelial markers on VEGFR3-positive cells isolated from GBM. The demonstration of a complete angiogenic signaling system that is dependent on tumor grade may influence the traditional paradigm of glioma angiogenesis and may provide a basis for more effective anti-angiogenic treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17115285     DOI: 10.1007/s11060-006-9272-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  50 in total

Review 1.  VEGF-targeted therapy: therapeutic potential and recent advances.

Authors:  Lee S Rosen
Journal:  Oncologist       Date:  2005 Jun-Jul

Review 2.  VEGF function in vascular pathogenesis.

Authors:  Yin-Shan Ng; Dominik Krilleke; David T Shima
Journal:  Exp Cell Res       Date:  2005-12-05       Impact factor: 3.905

3.  Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.

Authors:  Antonella N Witmer; Harriet G Blaauwgeers; Herbert A Weich; Kari Alitalo; Gijs F J M Vrensen; Reinier O Schlingemann
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

4.  Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia.

Authors:  Antonella N Witmer; Jiapei Dai; Herbert A Weich; Gijs F J M Vrensen; Reinier O Schlingemann
Journal:  J Histochem Cytochem       Date:  2002-06       Impact factor: 2.479

5.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.

Authors:  T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

6.  VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.

Authors:  W Debinski; B Slagle-Webb; M G Achen; S A Stacker; E Tulchinsky; G Y Gillespie; D M Gibo
Journal:  Mol Med       Date:  2001-09       Impact factor: 6.354

7.  Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer.

Authors:  Fengshi Chen; Kazumasa Takenaka; Eiji Ogawa; Kazuhiro Yanagihara; Yosuke Otake; Hiromi Wada; Fumihiro Tanaka
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

8.  Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.

Authors:  Rui-Cheng Ji; Masahiro Miura; Peng Qu; Seiji Kato
Journal:  Microsc Res Tech       Date:  2004-06-15       Impact factor: 2.769

9.  Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.

Authors:  Antoine Alam; Jean-Pascal Herault; Pauline Barron; Benoit Favier; Pierre Fons; Nathalie Delesque-Touchard; Isabelle Senegas; Patricia Laboudie; Jacques Bonnin; Cecile Cassan; Pierre Savi; Bruce Ruggeri; Peter Carmeliet; Françoise Bono; Jean-Marc Herbert
Journal:  Biochem Biophys Res Commun       Date:  2004-11-12       Impact factor: 3.575

Review 10.  Molecular mechanisms of lymphangiogenesis in health and disease.

Authors:  Kari Alitalo; Peter Carmeliet
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  24 in total

1.  ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases.

Authors:  Jayanta K Das; Norbert F Voelkel; Quentin Felty
Journal:  Microvasc Res       Date:  2015-02-07       Impact factor: 3.514

2.  Genome-wide discovery of functional transcription factor binding sites by comparative genomics: the case of Stat3.

Authors:  Francesco Vallania; Davide Schiavone; Sarah Dewilde; Emanuela Pupo; Serge Garbay; Raffaele Calogero; Marco Pontoglio; Paolo Provero; Valeria Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

Review 3.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Revival of the VEGF ligand family?

Authors:  Simone P Niclou
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

5.  Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma.

Authors:  Guiyan Xu; Jian Yi Li
Journal:  Tumour Biol       Date:  2016-02-09

6.  Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells.

Authors:  S Grau; J Thorsteinsdottir; L von Baumgarten; F Winkler; J-C Tonn; C Schichor
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

Review 7.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

8.  Podoplanin increases migration and angiogenesis in malignant glioma.

Authors:  Stefan J Grau; Fabian Trillsch; Joerg-Christian Tonn; Roland H Goldbrunner; Elfriede Noessner; Peter J Nelson; Irene von Luettichau
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 9.  New molecular targets in angiogenic vessels of glioblastoma tumours.

Authors:  Joshua C Anderson; Braden C McFarland; Candece L Gladson
Journal:  Expert Rev Mol Med       Date:  2008-08-07       Impact factor: 5.600

Review 10.  Angiogenesis as a therapeutic target in malignant gliomas.

Authors:  Andrew S Chi; A Gregory Sorensen; Rakesh K Jain; Tracy T Batchelor
Journal:  Oncologist       Date:  2009-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.